Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)
3210 Merryfield Row
San Diego
California
92121
United States
Tel: 858-450-2000
Website: http://www.jnjpharmarnd.com/
44 articles about Johnson & Johnson Pharmaceutical Research & Development, LLC (CA)
-
FDA (JOBS) Approves Johnson and Johnson Pharmaceutical Research and Development, LLC (CA)'s (JOBS) CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD
6/27/2008
-
Johnson and Johnson Pharmaceutical Research and Development, LLC (CA) Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
5/14/2008
-
Johnson and Johnson Pharmaceutical Research and Development, LLC (CA) New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
5/12/2008
-
Johnson and Johnson Pharmaceutical R&D (NJ) Release: Three Phase III Trials Show Rivaroxaban Outperformed Enoxaparin in Preventing Venous Thromboembolism After Major Orthopedic Surgery
12/10/2007
-
Elan Corporation PLC Announces the Johnson and Johnson Pharmaceutical Research and Development, LLC (CA) Submission of a New Drug Application to the FDA
10/29/2007
-
Johnson and Johnson Pharmaceutical Research and Development, LLC (CA) New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
9/19/2007
-
Ortho Biotech Products, L.P. Release: Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in The New England Journal of Medicine
9/6/2007
-
Melior Discovery Enters New Pharmaceutical Collaboration
8/6/2007
-
FDA Issues Approvable Letter For Johnson and Johnson Pharmaceutical Research and Development, LLC (CA)'s Paliperidone ER For The Treatment Of Schizophrenia
10/2/2006
-
Epigenomics AG Enters Into Agreement With Johnson and Johnson Pharmaceutical Research and Development, LLC (CA)
8/7/2006
-
Johnson and Johnson Pharmaceutical Research and Development, LLC (CA) Release: Investigational Drug Paliperidone ER Significantly Delayed Symptom Recurrence In Clinical Study Of Patients With Schizophrenia
7/13/2006
-
Illumina, Inc. To Conduct Custom Genotyping For Johnson and Johnson Pharmaceutical Research and Development, LLC (CA)
7/13/2006
-
Johnson & Johnson Pharmaceutical Research and Development, LLC Release: Clinical Study Of Investigational Drug Paliperidone ER Demonstrated Efficacy And Tolerability In The Treatment Of Patients With Schizophrenia
5/23/2006
-
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) (MLNM) And Johnson And Johnson and Johnson Pharmaceutical Research and Development, LLC Initiate Phase III Clinical Trial With VELCADE(R) For Injection In Follicular Non-Hodgkin's Lymphoma
4/18/2006
-
Entelos, Inc. Announces Expanded Collaboration With Johnson and Johnson Pharmaceutical Research and Development, LLC (CA)
3/16/2006
-
PamGene Platform Adopted For Kinase Drug R&D Program: Collaboration With Johnson and Johnson Pharmaceutical R&D (NJ)
3/9/2006
-
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) Achieves $10 Million Milestone Payment From Johnson and Johnson Pharmaceutical Research and Development, LLC (CA)
3/9/2006
-
Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) And Johnson and Johnson Pharmaceutical R&D (NJ) Initiate Randomized Phase II Trial Of VELCADE(R) (Bortezomib) For Injection In Non-Small Cell Lung Cancer
3/6/2006
-
GeneGo, Inc. Expands License With Johnson and Johnson Pharmaceutical R&D (NJ) To Include MetaBase Access
2/20/2006
-
Hurel Corporation And Johnson and Johnson Pharmaceutical R&D Enter Into Joint Scientific Collaboration
7/25/2005